TABLE 1.
Clinical and laboratory characteristics by different test resultsa
| Variable | Value |
P valueb | Value |
P valuec | ||
|---|---|---|---|---|---|---|
| NAAT+/toxin+ (n = 32) | NAAT+/toxin− (n = 32) | NAAT+/toxin− (n = 32) | NAAT−/toxin− (n = 230) | |||
| Antibiotics within 30 days (n [%]) | 14 (43.8) | 12 (37.5) | 0.6107 | 12 (37.5) | 53 (23.0) | 0.0761 |
| History of CDI (n [%]) | 6 (18.8) | 5 (15.6) | 0.7404 | 5 (15.6) | 10 (4.4) | 0.0101 |
| Clinically significant diarrhead (n [%]) | 27/27 (100) | 27/27 (100) | >0.9999 | 27/27 (100) | 167/185 (90.3) | 0.0902 |
| WBC >15,000/mlc (n [%]) | 7/28 (25.0) | 5/24 (20.8) | 0.7222 | 5/24 (20.8) | 23/186 (12.4) | 0.2556 |
| Creatinine >1.5 mg/dlc (n [%]) | 7/28 (25.0) | 6/24 (25.0) | 0.4791 | 6/24 (25.0) | 28/187 (15.0) | 0.6910 |
| Length of stay, inpatients (days) (mean [SD]) | 14.2 (16.9), n = 15 | 7.6 (4.8), n = 14 | 0.7424 | 7.6 (4.8), n = 14 | 7.5 (9.2), n = 123 | 0.1900 |
| Resolution of symptoms within 14 daysc (n [%]) | 21/24 (87.5) | 17/23 (73.9) | 0.3606 | 17/23 (73.9) | 133/160 (83.1) | 0.4990 |
| 30-day CDI relapse (n [%]) | 4 (12.5) | 0 (0) | 0.0389 | 0 (0) | 0 (0) | >0.9999 |
a
NAAT, nucleic acid amplification test; CDI, C. difficile infection; WBC, white blood cell count.
b
Test for comparison between the NAAT+/toxin+ and NAAT+/toxin− groups.
c
Test for comparison between the NAAT+/toxin− and NAAT−/toxin− groups.
d
Testing for WBC and creatinine was not performed on 58 and 57 patients, respectively. There was no information available on symptom resolution and medical chart-confirmed presence of clinically significant diarrhea in 87 and 57 patients, respectively. Percentages are reported as proportions of patients in each group with data available.